Illimis Therapeutics

About Illimis Therapeutics

Illimis Therapeutics is dedicated to translating cutting-edge science into innovative medicines, focusing on sustainable innovation to improve the quality of life for patients and their families. The company emphasizes respect, collaboration, integrity, accountability, and a mission-driven approach to contribute to humanity through life science and technology development.

Products & Services

GAIA-Aβ (AD Moonshot):A groundbreaking approach to Alzheimer’s treatment aimed at improving the quality of life for patients and families by addressing issues like ARIA found in existing therapies.

GAIA Platform:An innovative platform focused on developing treatments for intractable diseases through advanced scientific technologies.

Specialties

Central Nervous System (CNS) Drug Development Alzheimer’s Disease Treatment Neuroimmune Diseases TAM Receptor-based Therapies Inflammation-Free Drug Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 42000000 MR: - FA: 58 billion KRW $42 million FAN: 42000000	D: 2025-07-14 FD: 2025-07-14	18 investors

Series B Latest

2025-07-14

$42.0M

18 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Park Sang-hoon

CEO

K

Kim Chan-hyuk

Professor

Recent News